Top Diagnostics Startups in 2026

Recent groundbreaking scientific insights into the genetic causes and biological processes underlying neurodegenerative diseases offer an unprecedented opportunity for the discovery and development of effective medicines for Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases. The programs in our portfolio are based on our deep expertise in the biology of neurodegenerative diseases and the blood-brain barrier. Our core portfolio currently consists of programs at various stages of clinical and preclinical development and have the potential to meaningfully improve the lives of patients by directly addressing a cause or risk factor for the disease. We are committed to partnering with patients to discover and develop new, effective medicines for neurodegenerative diseases.

The HemoLink expands blood testing with a virtually painless, one-step device that people can use at home. Once collected, the tube attached to the device can be placed into existing lab instruments and run for standard diagnostic tests.

Qure AI is a healthtech startup that uses artificial intelligence assistance for medical imaging diagnostics. The company's mission is to make healthcare affordable and accessible using the power of artificial intelligence. They build deep learning solutions that aid physicians with routine diagnosis and treatment, allowing them to spend more time with patients. Qure AI was founded in 2016 and is based in Mumbai, Maharashtra.

IonPath is a Stanford University spin-out with a vision to transform clinical pathology and tumor imaging, a $10B+ market, with the company's novel, highly multi-parametric imaging technology, Multiplexed Ion Beam Imaging (MIBI). IonPath's MIBI is a step-change improvement over the current leading tumor imaging method, immunohistochemistry (IHC). MIBI enables researchers, pathologists, and clinicians to quantitatively analyze and visually display the complex interactions among cancer tumor cells, proteins, antibodies, T-cells, and other relevant features on cells' surfaces and interiors. Understanding these biological players and their interactions should substantially improve cancer research and drug discovery, produce novel diagnostics, and transform the study of disease mechanisms such as cancer ("pathology"). IonPath will develop and commercialize services, instruments, reagents, and ultimately diagnostic tests based on MIBI technology.

Clinia is healthcare platform on a mission to transform the conventional patients and healthcare providers experience. Technology is used to make it accessible, efficient and convenient to the masses.

Mammoth biosciences is harnessing the diversity of nature to power the next generation of crispr products. through its discovery of novel crispr systems, the company is enabling the full potential of its platform to read and write the code of life. with a distinguished team including co-founder and crispr-cas gene editing co-inventor jennifer doudna, mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more.

Welcome to HeartFlow, recipient of the 2011 EuroPCR Innovation award. Read to learn about non-invasive FFRCT (computed FFR), DISCOVER-FLOW and DeFACTO studies

The risk of dying in the 30 days after surgery is 1,000-fold higher than intraoperative risk. The 30 days after surgery, if considered a disease, would be the third-leading cause of death in the United States. General ward respiratory failure is common, profound, and prolonged. We are looking to dent this substantial cause of morbidity and mortality with our AI engine powered by our medical-grade contactless radar sensor, clinic software, and proprietary algorithms.

The human microbiome is the next frontier of precision medicine. Just like our genes, our microbiome is unique and can help predict our health in many ways, from our disease risk to how the drugs we take effect us. Most importantly, unlike our genes, it's dynamic - so can be harnessed for better health. There's just one problem - that same dynamism makes it extremely challenging to study, and that slows progress. Microbiome researchers need more data to turn potential into reality. That's why we're creating novel tools to track, analyze, and store daily microbiome profiles of clinical trial participants, providing vastly more data than is possible with current tools, all for a fraction of the cost. This gives investigators far deeper insight into how the microbiome influences and is influenced by clinical interventions. The outcome? Microbiome-based prescriptions and solutions that are personalized to meet patient needs.